Physician profile

John Ross Macdonald

Internal Medicine · Abington, PA

NPI 1275062903

$2,276.02

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$21.19

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $1,089.61 2019
Abbvie INC. $246.86 2019
Amarin Pharma, INC. $225.68 2019
Astrazeneca Pharmaceuticals Lp $208.78 2019-2020
E.R. Squibb & Sons, L.L.C. $144.05 2022-2024 Eliquis
Genentech USA, INC. $134.33 2019
Novo Nordisk INC $113.27 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $95.39 2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $18.05 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Ross Macdonald

$2,276.02

in general payments reported 2019-2025

Years
2019-2024
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/4131985/john-ross-macdonald

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.